Researchers investigated the role of interleukin-1 inhibition in improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes.
Researchers assessed the risk for rheumatoid arthritis in patients receiving antibiotics.
Researchers examined the effects of HLA-B27 and HLA-DRB1 alleles on the intestinal microbiome of healthy individuals.
The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
The model improves anti-TNF drug selection and the effect of genetic markers across multiple cohorts.
This is the first study to examine the real-world outcome of the management of RA using neutrophil-lymphocyte ratio.
Results of an investigational US pilot study have shown that a proprietary bioelectronic microregulator device, manufactured by SetPoint Medical, can benefit patients with rheumatoid arthritis.
Upadacitinib monotherapy resulted in improvements in clinical and functional outcomes vs continuing methotrexate in a population of methotrexate inadequate-responders with active RA.
Study compared efficacy and safety of filgotinib with and without methotrexate in patients with rheumatoid arthritis who were naive to methotrexate therapy.
Researchers sought to determine whether exposure to methotrexate for rheumatoid arthritis may lead to interstitial lung disease.
Researchers evaluated the effectiveness of 2 tapering strategies in patients with RA who had achieved controlled disease activity.
In patients with rheumatoid arthritis treated with anti-inflammatory medications, long-term persistent pain was found to be common and may be predicted by higher levels of disability and a history of smoking.
Dietary intake of fish did not have a protective effect against rheumatoid arthritis.
The inclusion of tender joint count in the Composite Disease Activity Score may contribute to misleading information about inflammatory activity.
The use of abatacept as an initial bDMARD for the treatment of patients with rheumatoid arthritis is associated with a slightly elevated risk for cancer overall.